CAPSL Inhibitors
CAPSL inhibitors encompass a range of chemical compounds that act on specific signaling pathways, with the end result being a decrease in CAPSL activity. The primary pathways targeted by these inhibitors include the EGFR, ERK/MAPK, PI3K/AKT, JNK, and p38 MAPK pathways. A majority of these compounds, such as genistein, U0126, quercetin, LY294002, wortmannin, apigenin, resveratrol, and EGCG, act on the EGFR, ERK/MAPK, and PI3K/AKT pathways, which are critical signaling pathways that can influence calcium signaling, a process in which CAPSL is involved. By inhibiting these pathways, these compounds can effectively reduce the functional activity of CAPSL.
Other inhibitors target different but related pathways. For example, PD98059 inhibits the MAPK pathway, SB203580 acts on the p38 MAPK pathway, and SP600125 hinders the JNK pathway. These pathways are believed to intersect with the biochemical processes in which CAPSL is involved. Inhibiting these pathways can also result in decreased functional activity of CAPSL. The last compound, curcumin, is unique in that it has the capability to impact both the JNK and p38 MAPK signaling pathways, further diversifying the range of pathways that can be targeted to inhibit CAPSL activity. This extensive variety of chemical inhibitors, each with distinct pathway targets, underscores the complex regulatory network that controls CAPSL activity. It's essential to note that while each of these inhibitors actson a distinct signaling pathway, their collective effect on CAPSL inhibition highlights the interconnected nature of these pathways and the multifaceted regulatory mechanisms modulating CAPSL activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein inhibits the EGFR pathway. Since CAPSL is involved in calcium signaling, and this pathway can regulate calcium levels, Genistein's inhibition of the EGFR pathway can lead to decreased CAPSL activity. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin inhibits PI3K, which can modulate calcium signaling. As CAPSL is involved in calcium signaling, Quercetin's inhibition of PI3K can lead to decreased CAPSL activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent PI3K inhibitor. As CAPSL is involved in calcium signaling, which can be influenced by the PI3K/AKT pathway, inhibition of this pathway by LY294002 can reduce CAPSL activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of the MAPK pathway, which can influence calcium signaling, in which CAPSL is involved. By inhibiting this pathway, PD98059 can decrease the activity of CAPSL. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor. As CAPSL is involved in calcium signaling, which can be influenced by the PI3K/AKT pathway, inhibition of this pathway by Wortmannin can reduce CAPSL activity. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $32.00 $210.00 $720.00 $1128.00 $2302.00 $3066.00 $5106.00 | 22 | |
Apigenin inhibits the PI3K/AKT pathway, which can influence calcium signaling, a process in which CAPSL is involved. Thus, Apigenin's inhibition of this pathway can lead to decreased CAPSL activity. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol is known to inhibit the PI3K/AKT pathway. As CAPSL is involved in calcium signaling, Resveratrol's inhibition of this pathway can lead to decreased CAPSL activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits the PI3K/AKT pathway, which can influence calcium signaling, a process in which CAPSL is involved. Thus, EGCG's inhibition of this pathway can lead to decreased CAPSL activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits the p38 MAPK pathway. If CAPSL is involved in this pathway, its inhibition by SB203580 can result in decreased CAPSL activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits the JNK pathway. This pathway's inhibition can lead to a decrease in CAPSL activity, as this protein is thought to interact with the JNK pathway. | ||||||